Contingencies and commitments
Contractual obligations and commitments
We entered into lease agreements for office and laboratories which qualify as operating leases. We also have certain purchase commitments principally with contract research organizations and certain collaboration partners.
On 30 September 2018 we had outstanding obligations for future minimum rent payments and purchase commitments, which become due as follows:
(thousands of €) |
Total |
Less than 1 year |
1–3 years |
3–5 years |
More than 5 years |
Operating lease obligations |
27,925 |
4,724 |
9,391 |
6,597 |
7,213 |
Purchase commitments |
195,518 |
119,792 |
66,228 |
9,498 |
– |
Total contractual obligations & commitments |
223,442 |
124,515 |
75,619 |
16,095 |
7,213 |
On 31 December 2017, we had outstanding obligations for future minimum rent payments and purchase commitments, which become due as follows:
(thousands of €) |
Total |
Less than 1 year |
1–3 years |
3–5 years |
More than 5 years |
Operating lease obligations |
26,346 |
4,150 |
7,820 |
6,010 |
8,366 |
Purchase commitments |
65,246 |
53,010 |
11,233 |
1,002 |
– |
Total contractual obligations & commitments |
91,592 |
57,160 |
19,053 |
7,012 |
8,366 |
In addition to the tables above, we have a contractual cost sharing obligation related to our collaboration agreement with Gilead for filgotinib. The contractual cost sharing commitment amounted to €88.5 million at 30 September 2018 (€129.0 million at 31 December 2017), for which we have direct purchase commitments of €5.0 million at 30 September 2018 (€10.1 million at 31 December 2017) reflected in the tables above.
Contingent liabilities and assets
We refer to our annual report 2017 for contingent liabilities and assets.